← boardnext 2027-04
CGTX
Cognition Therapeuticsdistress 2/10 · well-funded / low risk$0.98+2%today-69% from 52w high
Lead: early Alzheimer's disease · est. market ~$8B (approx, global)
Revenue
pre-revenue
Liquidity
$31M
Runway
1.5 yrs
Shares 1y
+22%
Price & events
-32.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+2.0%
1D
+4.4%
1W
-40.5%
1M
-22.1%
3M
-31.4%
6M
+21.9%
1Y
-45.2%
2Y
—
5Y
-92.3%
All
Overview
- Market Cap
- $87.81M
- Volume
- 13.14K
- 52 Week Range
- $0.57 – $3.18
- Total Shares
- 89.50M
- Float Shares
- 81.83M
- Short %
- 8.56%
- % Held by Insiders
- 1.37%
- % Held by Institutions
- 25.02%
- RVOL
- 0.01x
- Beta
- 1.75
Pipeline stages · 1 programs
CT1812
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-04 Estimated 50% readout ~2027-05-16 | Phase 2 | CT1812 | Early Alzheimer's Disease | — | active not recruiting |
Catalyst news & presentations · 7
- 2H 2027Guided 55%readoutPhase 2zervimesine · Topline data from START Phase 2 trialSEC 8-K
- mid-2027Guided 55%trial initiationsecondaryPhase 3zervimesine (CT1812) · Registrational program expected to begin.SEC 8-K
- JulyEstimated 45%conferencedata presentationsecondaryPhase 2zervimesine (CT1812) · Present additional Phase 2 SHIMMER trial analyses at AAIC.SEC 8-K
- 2026-06-24fda agreementzervimesine (CT1812) · FDA aligned on DLB psychosis as approvable outcome and pivotal trial design.SEC 8-K
- 2026-03-02fda agreementzervimesine · Received final minutes from FDA Type C meeting confirming registrational path for DLB psychosis.SEC 8-K
- second quarter of 2025readoutPhase 2zervimesine · Full analysis of MAGNIFY Phase 2 trial in geographic atrophy secondary to dry AMD.SEC 8-K
- June 2025trial initiationsecondaryzervimesine · Launch of expanded access program COG1202, first site activated at Banner Sun Health Research Institute.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $4 (+257% upside) · 4 analysts
- 2026-03-27Chardan CapitalBuy
- 2025-12-04HC Wainwright & Co.Buy
- 2025-11-21B. Riley SecuritiesBuy
- 2025-11-19HC Wainwright & Co.Buy
- 2025-08-08Chardan CapitalBuy
- 2025-06-26HC Wainwright & Co.Buy
Competitors — early Alzheimer's disease
Recent news
- 2026-07-18Cognition Therapeutics (CGTX) Edges Higher as Biotech Stock Tests Key Resistance - Analyst Upgrade Stocks - dars.gov.et
- 2026-07-17Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Invest In Growth? - Sahm
- 2026-07-15Cognition Therapeutics (CGTX) Edges Lower as Stock Hovers Near Key Support Level - RVOL Breakout - dars.gov.et
- 2026-07-13Cognition Therapeutics CEO Lisa Ricciardi to Participate in B. Riley Mind, Muscle & Vision Summit Fireside Discussion - Quiver Quantitative
- 2026-06-29Cognition Therapeutics Slides Amid Sector Weakness; Key Support Levels in Focus - Trading Ideas - dars.gov.et
- 2026-06-26Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain - Seeking Alpha
- 2026-06-25Cognition Therapeutics, Inc. Actuals & Estimates (NASDAQ:CGTX) - TradingView
- 2026-06-25CGTX Forecast — Price Target — Prediction for 2027 - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.